Here, we present partial bile duct ligation as a surgical model of liver injury and regeneration in rodents.
In rodents, complete bile duct ligation (cBDL) of the common bile duct is an established surgical technique for studying obstructive cholestasis and bile duct proliferation. However, long-term experiments can lead to increased morbidity and mortality. In select mouse strains with underlying liver disease, meaningful comparisons can be made even with ligation of a single lobe of the liver, which can reduce animal losses and expenses. Here, we describe partial bile duct ligation (pBDL) in the mouse, in which only the left hepatic bile duct is ligated, causing biliary obstruction in the left lobe but not the remaining lobes. With careful microsurgical technique, pBDL experiments can be cost-effective, since the unligated lobe serves as an internal control to the ligated lobes, when subjected to the same conditions in the same animal. Unlike cBDL, a separate sham-operated control group is not necessary. pBDL is highly useful to directly compare localized versus systemic effects of cholestasis and other retained bile components. pBDL can also be repurposed as a novel method to investigate mechanisms related to medications and cell migration.
Surgical models of acute liver injury and repair, such as partial hepatectomy or common bile duct ligation (cBDL), have been used for decades in rodents to study liver regeneration and pathobiology1,2. In cBDL, the common bile duct (which drains all bile produced in the liver) is ligated, resulting in obstructive cholestasis, inflammation, and fibrosis in the first 2-3 weeks following surgery, with eventual progression to cirrhosis3. Bile duct proliferation, transdifferentiation, and induction of resident liver progenitor cells are also features of cBDL4,5. Although cBDL elucidates specific mechanisms of obstructive cholangiopathy, which are well-characterized with reproducible outcomes in wild-type mice and in those strains with normal livers6,7,8, the procedure can be technically demanding in some transgenic mouse models of liver diseases, requiring more animals than anticipated due to the higher morbidity and mortality of biliary obstruction over time. This technique is also beneficial for studying transgenic mice with underlying liver disease, which might not otherwise tolerate the stress of prolonged time course experiments following cBDL.
pBDL can provide a reasonable alternative to help overcome some of these challenges. Initial pBDL studies in wild-type mice aimed to distinguish locally acting and systemic mediators of inflammation9. In pBDL, the main biliary confluence of the right and left hepatic bile ducts above the common bile duct is carefully visualized at the hilum, and only the left hepatic bile duct is ligated to generate a localized obstructive cholestasis. pBDL offers several advantages to cBDL. In pBDL, the unligated right lobe serves as an identically matched internal control for the ligated left lobe, subjected to the same systemic effects, such as nutritional status or circulating factors. Although systemic pro-inflammatory mediators were present, Osawa et al. observed less fibrosis and necrosis in the unligated lobes, but increased inflammatory cells and transforming growth factor-β expression in the ligated lobe9.
More recently, pBDL has been redefined to study liver parenchymal effects of retained bile10. By using the same animal for internal control (unligated "sham") and experimental groups, pBDL effectively halves the number of animals needed per experiment, which in turn is more cost-effective. The mice tolerate the effects of pBDL much better, so that the ideal time course experiment (≥2 weeks) can be achieved in the ligated lobe. Most importantly, pBDL can distinguish direct intrahepatic effects of obstructive cholestasis and retained bile components in the ligated lobe, compared to the unligated control lobe. Overall, pBDL is an attractive method to study lobe-specific effects of localized cholestasis in the liver.
All procedures were conducted in accordance with ethical guidelines of the Institutional Animal Care and Use Committee of the University of Pittsburgh.
1. Basic Techniques and Common Procedures
2. Presurgical Preparation
3. Partial Bile Duct Ligation Operation
4. Postoperative Treatment and Follow-Up
For this typical experiment, pBDL was performed in triplicate PiZ transgenic mice, which recapitulate the human liver disease found in alpha-1 antitrypsin (A1AT) deficiency. The PiZ mouse overexpresses a transgene consisting of multiple genomic fragments of DNA that contain the coding regions of the mutant human A1AT gene and promoter, together with introns and ~2 kilobases of upstream and downstream flanking regions14,15. Normal A1AT is a secreted serum protein produced in the liver. The mutant form of A1AT generates insoluble protein aggregates that spontaneously accumulate in the liver causing toxic stress. The experiments utilized 3-month old male PiZ mice, which express the most severe phenotype of this disease, when the protein aggregation peaks16.
Serum liver biochemistries were compared in pBDL and cBDL PiZ mice (Table 1)10. The liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are biomarkers of hepatocellular injury, while total serum bilirubin (TSB) measures the degree of cholestasis. Overall, mice subjected to pBDL did not show signs of severe liver injury or cholestasis, as their serum values were similar to baseline10. It is important to note that mice with failed pBDL (due to technical problems, such as bile duct or vascular injuries) will show serum values similar to cBDL mice, with significantly elevated liver enzymes and TSB. Clinically, mice with failed pBDL will appear more jaundiced and distressed, with findings of bile leaks, ascites, peritonitis, and/or hematoma, and will ultimately need to be sacrificed.
Since mice subjected to pBDL develop lobe-specific obstructive cholestasis, they do not acquire the distended, dark, bile-filled gallbladder seen in cBDL. Only the ligated lobe appears paler in color, while the unligated lobes will maintain their normal, dark, reddish-brown coloration (Figure 3). There are key differences in liver histology as well, with increased bile duct proliferation and fibrosis in the ligated lobe (Figure 4).10
Table 1: Representative serum liver biochemistries from partial bile duct ligation (pBDL) compared to complete bile duct ligation (cBDL)10. Each time point represents 3-4 mice. Note PiZ transgenic mice are on a c57/bl6 background. Lab reference ranges are also given in parentheses. (WT, wild-type; TSB, total serum bilirubin; ALT, alanine aminotransferase; ALP, alkaline phosphatase).
Figure 1:Exposure of abdominal cavity and hepatobiliary system. (A) Small intestines are gently retracted to avoid bowel injury, and the connecting ligaments are cut free from retroperitoneum. (B) Liver is gently retracted to allow maximal visualization of the biliary tree at the hepatic hilum (arrow). Please click here to view a larger version of this figure.
Figure 2: Partial bile duct ligation. (A) The blunt end of the surgical needle is used to carefully encircle the nylon suture around the left hepatic bile duct, above the confluence to the common bile duct (original magnification 40x). (B) Successful ligature of the left hepatic bile duct, which normally drains the left liver lobe. The remaining bile ducts are unligated (original magnification 40X). Please click here to view a larger version of this figure.
Figure 3: Gross appearance of the WT (c57/b6) mouse liver 14 days after pBDL. Note that the ligated left lobe appears paler in color (arrows), while the unligated lobes retain their normal, dark, reddish-brown coloration. Please click here to view a larger version of this figure.
Figure 4: Lobe-specific changes in representative liver tissue sections from day 14 pBDL comparing unligated right (R) lobe to ligated left (L) lobe in WT (c57/b6) mice. (A) Hematoxylin and eosin (H&E) staining showing increased bile duct proliferation (arrows) in the ligated lobe. (B) Sirius red stain showing bridging fibrosis accompanying bile duct proliferation in the ligated lobe. Histology for the PiZ mouse has been previously reported10. Please click here to view a larger version of this figure.
Although cBDL is the most common experimental technique for obstructive cholestasis, it can present multiple challenges in rodents. Depending on the number of post-operative days required to achieve an endpoint, the animals can experience significant morbidity and mortality as time progresses. The degree of tissue injury and biliary necrosis is further exacerbated when working with some transgenic mouse models of liver disease, which demonstrate abnormal liver parenchyma and function at baseline. Compared to cBDL, reports of pBDL are limited, but this technique can be applied as an alternative in select experiments to reduce negative outcomes and animal losses.
Variations in the pBDL method have also been reported. In the method of Heinrich et al., an external curved needle is placed adjacent to the common bile duct, followed by ligature around both the common bile duct and the needle17. The needle is then removed prior to abdominal wall closure, resulting in limited bile flow through a narrowed lumen (i.e., subtotal obstruction) of the bile duct17. During this procedure, the gall bladder is also removed to prevent cholecystitis17. The authors concluded that this method was more beneficial to study acute cholestasis rather than chronic changes17. In contrast, the pBDL method we described here is tightly controlled, with both ligated and unligated ("sham") lobes in the same animal, so less animals are required per experiment. Even transgenic mice with severe underlying liver disease can be sustained for longer end points (2-3 weeks). Care must be taken to fully expose and identify the biliary tree using microdissection techniques, with limited manipulation of vascular structures and bile ducts to prevent injury.
In the ideal experiment, tissues from the ligated (left) and unligated (right) lobes will be harvested at the same time, so direct comparisons of bile secretory function and transporters can be made using histologic and molecular techniques. Although serum liver biochemistries will not reflect severe cholestasis, the ligated lobe will demonstrate histologic changes associated with obstructive cholestasis10. This model is useful to study direct microenvironmental effects of retained bile components (e.g., bile acids, lipids, cholesterol) within the liver. As a future study, pBDL may be considered to investigate cholehepatic shunting, where certain bile acids and drugs are reabsorbed directly from cholangiocytes to hepatocytes18,19. Endogenous bile acids inefficiently conjugated by hepatocytes are passively absorbed by biliary epithelium to undergo cholehepatic shunting as well, leading to hypercholeresis and alkanlinization of the bile by increased bicarbonate secretion20. Application of the pBDL technique could facilitate drug discovery by identifying pharmacologic mechanisms for novel bile acid therapeutics under investigation for liver disease.
Additional applications for pBDL can extend beyond the biliary tree. Reversibility of cBDL and its associated effects has been described, and this may also be applied to pBDL with direct comparison to the internal control21. Similarly, longitudinal in vivo bioimaging of fluorescent reporter expression in mouse liver has been studied after cBDL22, with powerful implications for pBDL experiments. Furthermore, rodent experiments using pBDL have the potential to incorporate lineage tracing or "homing" of circulating cells, such as bone marrow-derived mesenchymal cells, to the site of liver injury, allowing them to be tracked in vivo with more precision23,24,25.
Clearly, there are widespread applications for pBDL alone as an internally controlled and reproducible technique to study liver injury and repair, along with biliary physiology and drug metabolism. For experiments that aim to evaluate the progression and systemic effects of chronic cholestasis, cBDL is still the most preferred method; however, pBDL would still add complementary data to support such findings.
The authors have nothing to disclose.
Dr. Khan acknowledges grant support from NIH/NICHD K12HD052892, the Alpha-1 Foundation, the Hillman Foundation, and the Pittsburgh Liver Research Center. Dr. Michalopoulos acknowledges grant support from NIH/NIDDK P01DK096990. We appreciate the excellent and generous technical assistance of Anne Orr. We are also grateful to Dr. David A. Geller for providing access to the Transplant/Rodent Microsurgery lab.
Microscope-Leica Wild M650, 6–40× magnification | Leica Microsystems | n/a | |
Tec 3 isoflurane funnel fill vaporizer | General Anesthetic Services | n/a | |
Stevens Tenotomy Scissors | Accurate Surgical & Scientific Instruments Corporation | ASSI.9193 | |
Adson Forceps | Fine science tools | 11006-12 | |
Mosquito classic delicate hemostatic forceps | Codman | 30-4472 | |
Micro-retractor | Murdock; Roboz Surgical Instrument | RS-6550 | |
Nonwoven gauze sponges | Fisherband | 870-PC-DBL | |
Puritan 6” Small Cotton Swab w/Wooden Handle | Puritan Medical Products Company | 868-WCS | |
Dumont SS Forceps – Standard Tips/Straight/Inox/13.5cm | Fine science tools | 11203-23 | |
Dumont SS Forceps – Standard Tips/Angled 45°/Inox/13.5cm | Fine science tools | 11203-25 | |
Vannas Spring Scissors – 3mm Cutting Edge | Fine science tools | 15000-00 | |
Microneedle holder | Aesculap Surgical Instruments | FD231R | |
Micro AROSuture, sterile 10-0 nylon suture, 70 µm, TAP points | AROSurgical Instruments Corporation | T4A10N07 | |
4-0 Vicryl | Ethicon | J662H | |
5-ml Syringe | BD | 309646 | |
Falcon tissue culture dish, 60 × 15 mm | Corning | 353002 | |
Isoflurane, United States Pharmacopeia (USP) liquid for inhalation, 250 ml | Piramal Healthcare | NDC 66794-017-25 | |
Buprenex injectable (buprenorphine hydrochloride) | Reckitt Benckiser Pharmaceuticals | NDC 12496-0757-1 | |
Cefazolin for injection , USP | APP Pharmaceuticals | NDC 63323-238-61 | |
PVP scrub solution (povidone–iodine 7.5%) | Medline | NDC 12496-0757-1 | |
70% Ethanol | Decon Labs | 2716 | |
Phosphate Buffered Saline Without Calcium or Magnesium | LONZA | 17-516F | |
Sirius Red | Sigma | 365548 | |
Hematolxylin | Fisher (Richard-Allan Scientific) | 22-050-111 (7211) | |
Eosin | Anatech (Fisher) | 832 (NC9686037) | |
Formalin | Fisher | SF100-20 |